Literature DB >> 13829149

Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine.

A I GRAYZEL, J E SEEGMILLER, E LOVE.   

Abstract

Entities:  

Keywords:  GOUT/therapy; LEUCINE/related compounds; URIC ACID/metabolism

Mesh：

Substances：

Year:  1960        PMID： 13829149      PMCID： PMC293323          DOI： 10.1172/JCI104057

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  18 in total

1.  Excessive uric acid production in the human induced by 2-ethylamino-1,3,4-thiadiazole.

Authors:  J E SEEGMILLER; A I GRAYZEL; L LIDDLE
Journal:  Nature       Date:  1959-05-23       Impact factor: 49.962

2.  The enzymatic spectrophotometric method for determination of uric acid.

Authors:  L LIDDLE; J E SEEGMILLER; L LASTER
Journal:  J Lab Clin Med       Date:  1959-12

3.  Overproduction of uric acid as the cause of hyperuricemia in primary gout.

Authors:  J B WYNGAARDEN
Journal:  J Clin Invest       Date:  1957-10       Impact factor: 14.808

4.  Failure to detect consistent overincorporation of glycine-1-C14 into uric acid in primary gout.

Authors:  J E SEEGMILLER; L LASTER; L V LIDDLE
Journal:  Metabolism       Date:  1958-07       Impact factor: 8.694

5.  Control of pyrimidine biosynthesis in Escherichia coli by a feed-back mechanism.

Authors:  A B PARDEE; R A YATES
Journal:  J Biol Chem       Date:  1956-08       Impact factor: 5.157

6.  The metabolism of choline and its conversion to glycine in the rat.

Authors:  S SOLOWAY; D STETTEN
Journal:  J Biol Chem       Date:  1953-09       Impact factor: 5.157

7.  Incorporation of glycine nitrogen into uric acid in normal and gouty man.

Authors:  J D BENEDICT; M ROCHE; T F YU; E J BIEN; A B GUTMAN; D STETTEN
Journal:  Metabolism       Date:  1952-01       Impact factor: 8.694

8.  Inhibition of uric acid biosynthesis in birds by o-diazoacetyl-L-serine (azaserine) and 6-diazo-5-oxo-L-norleucine (DON).

Authors:  I H KRAKOFF; D A KARNOFSKY
Journal:  Am J Physiol       Date:  1958-10

9.  Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease.

Authors:  G B MAGILL; W P MYERS; H C REILLY; R C PUTNAM; J W MAGILL; M P SYKES; G C ESCHER; D A KARNOFSKY; J H BURCHENAL
Journal:  Cancer       Date:  1957 Nov-Dec       Impact factor: 6.860

10.  Clinical trials of O-diazoacetyl-L-serine (azaserine) in neoplastic disease.

Authors:  R R ELLISON; D A KARNOFSKY; S S STERNBERG; M L MURPHY; J H BURCHENAL
Journal:  Cancer       Date:  1954-07       Impact factor: 6.860
View more
  11 in total

1.  Uric acid production in gout.

Authors:  J E SEEGMILLER; A I GRAYZEL; L LASTER; L LIDDLE
Journal:  J Clin Invest       Date:  1961-07       Impact factor: 14.808

2.  A specific enzyme defect in gout associated with overproduction of uric acid.

Authors:  W N Kelley; F M Rosenbloom; J F Henderson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1967-06       Impact factor: 11.205

3.  Hyperuricaemia: some biochemical aspects.

Authors:  R W Watts
Journal:  Proc R Soc Med       Date:  1969-08

4.  The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism.

Authors:  W N Kelley; F M Rosenbloom; J E Seegmiller
Journal:  J Clin Invest       Date:  1967-09       Impact factor: 14.808

5.  The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Kathryn M Lemberg; Liang Zhao; Ying Wu; Vijayabhaskar Veeravalli; Jesse Alt; Joanna Marie H Aguilar; Ranjeet P Dash; Jenny Lam; Lukáš Tenora; Chabely Rodriguez; Michael T Nedelcovych; Cory Brayton; Pavel Majer; Jaishri O Blakeley; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

6.  Current concepts of hyperuricemia and gout.

Authors:  J R Klinenberg
Journal:  Calif Med       Date:  1969-03

7.  Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects.

Authors:  J E Seegmiller; J R Klinenberg; J Miller; R W Watts
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

8.  The treatment of gout and disorders of uric acid metabolism with allopurinol.

Authors:  M A Ogryzlo; M B Urowitz; H M Weber; J B Houpt
Journal:  Can Med Assoc J       Date:  1966-11-26       Impact factor: 8.262

9.  An efficient synthetic route to l-γ-methyleneglutamine and its amide derivatives, and their selective anticancer activity.

Authors:  Md Imran Hossain; Ajit G Thomas; Fakhri Mahdi; Amna T Adam; Nicholas S Akins; Morgan M Woodard; Jason J Paris; Barbara S Slusher; Hoang V Le
Journal:  RSC Adv       Date:  2021-02-10       Impact factor: 3.361

Review 10.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.